<![CDATA[Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026]]>
GLP-1 receptor agonists (GLP-1s) just may reduce the progression of some cancers. Specifically, in four of the seven cancer types analyzed in this real-world analysis — lung, breast, colorectal and liver — people who took GLP-1s were 38% to 50% less likely …